Drug intelligence / Profile preview

AR08

Development stage: Phase 2
Lead developer: Azurity Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

AR08 is a small molecule drug that acts as an adrenergic receptor alpha-2 (ADRA2) agonist. It was developed by Arbor Pharmaceuticals for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents, as well as vasomotor symptoms in menopausal females. The drug functions by stimulating alpha-2 adrenergic receptors, which are involved in modulating neurotransmitter release and vascular tone. Despite reaching phase 2 clinical trials for both ADHD and vasomotor symptoms, development of AR08 has been discontinued for these indications[3][5].

Targets

ADRA2A (α2A)

Beyond the preview

Go deeper on AR08.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AR08.

Explore the full profile